Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergoline.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples